key: cord-1053367-y9frjzzu authors: Kudo, Eriko; Israelow, Benjamin; Vogels, Chantal B.F.; Lu, Peiwen; Wyllie, Anne L.; Tokuyama, Maria; Venkataraman, Arvind; Brackney, Doug E; Ott, Isabel M.; Petrone, Mary E.; Earnest, Rebecca; Lapidus, Sarah; Muenker, M. Catherine; Moore, Adam J.; Casanovas-Massana, Arnau; Omer, Saad B.; Cruz, Charles S. Dela; Farhadian, Shelli F.; Ko, Albert I.; Grubaugh, Nathan D.; Iwasaki, Akiko title: Detection of SARS-CoV-2 RNA by multiplex RT-qPCR date: 2020-06-17 journal: bioRxiv DOI: 10.1101/2020.06.16.155887 sha: b25cfe8502860ae98d7f3b6d2c8c6ed12fffa820 doc_id: 1053367 cord_uid: y9frjzzu The current RT-qPCR assay recommended for SARS-CoV-2 testing in the United States requires analysis of three genomic targets per sample: two viral and one host. To simplify testing and reduce the volume of required reagents, we developed a multiplex RT-qPCR assay to detect SARS-CoV-2 in a single reaction. We used existing N1, N2, and RP primer and probe sets by the CDC, but substituted fluorophores to allow multiplexing of the assay. The cycle threshold (Ct) values of our multiplex RT-qPCR were comparable to those obtained by the singleplex assay adapted for research purposes. Low copies (>500 copies / reaction) of SARS-CoV-2 RNA were consistently detected by the multiplex RT-qPCR. Our novel multiplex RT-qPCR improves upon current singleplex diagnostics by saving reagents, costs, time and labor. The ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and associated coronavirus disease 2019 (COVID-19) has caused more than 7.5 million infections and killed more than 423,000 people as of June 14, 2020, and the virus continues to spread throughout the globe [1] . In the absence of a specific vaccine or effective therapy for the treatment of COVID-19, public health infection prevention measures, including contact tracing and isolation measures, are currently our only tool to stem transmission. However, testing, contact tracing and isolation measures require rapid and widespread testing. Here, we developed a quantitative reverse transcription PCR (RT-qPCR) assay for the detection of SARS-CoV-2 to allow for more rapid and widespread testing. While a number of primer and probe sets for the detection of SARS-CoV-2 RNA by RT-qPCR have become available since the identification of this novel virus, its broad deployment has been hampered partially by the availability of testing reagents. The current RT-qPCR assay developed by the CDC targets two different conserved segments of the viral nucleocapsid gene (N1 and N2) as well as the human RNase P gene as a sampling control [2] . This protocol therefore requires 3 reactions to be performed per patient sample, which, in addition to requiring a large amount of resources, also increases the chance for error. In an effort to reduce reagents, time, potential error and labor per sample, we developed a multiplex RT-qPCR for the detection of SARS-CoV-2. To do this, we utilized the existing N1 and N2 primer and probe sets published by the CDC; however, we substituted different fluorophores to enable multiplexing. We found the accuracy and specificity of this method to be similar to singleplex RT-qPCR. While there are commercially available tests that employ multiplex PCR, their methods remain proprietary to the companies and are not published. Important consideration in 5 this regard is the such tests are cost prohibitive in low and middle income countries in which COVID-19 pandemic is spreading. Therefore, this novel multiplex RT-qPCR assay provides the first publicly available multiplex PCR protocol, which provides equivalent diagnostic accuracy to current singleplex methods in fewer reactions and utilizes less reagents and time. Clinical samples from Yale-New Haven Hospital COVID-19 diagnosed inpatients and health care workers were collected as part of Yale's project IMPACT biorepository. RNA was extracted from nasopharyngeal and saliva samples using the MagMax Viral/Pathogen Nucleic Acid Isolation kit (ThermoFisher Scientific, Waltham, MA, USA), according to a modified protocol [3] . Full-length SARS-CoV-2 RNA (WA1_USA strain from University of Texas Medical Branch (UTMB); GenBank: MN985325) [4] was used as positive control for validation. Total RNA extracted from human embryonic kidney cell line 293T was used for detection of internal host gene control. All reactions were performed on a CFX96 Touch instrument (Bio-Rad, Hercules, CA, USA) using Luna Universal Probe One-Step RT-qPCR Kit (New England BioLabs, Ipswich, MA, USA) according to the manufacturer's protocol. A final reaction volume of 20 μl containing 5 μl 6 template was used. The following cycling conditions were applied; a cDNA synthesis 10 min/55℃, a hold step 1 min/95℃, and subsequently 45 cycles of denaturation 10 s/95℃ and annealing/elongation 30 s/55℃. Nuclease-free water was used as the non-template control. The primer pairs and probes for single-and multiplex RT-qPCR are shown in Table 1 . We calculated analytic efficiency of RT-qPCR assays tested with full-length SARS-CoV-2 RNA using the following formula. The limit of detection (LOD) was analyzed using 10-fold serially diluted full-length SARS-CoV-2 RNA into RNA extracted from pooled nasopharyngeal swabs from COVIDuninfected research participants. The Ct values and detection rates are shown in Table 2 . The slope of the standard curves for N1 and N2 were -3.36 and -3.52, respectively. The amplification efficiency was above 90% for both primer probe sets (Figure 1 ). All primer-probe sets and conditions were able to detect SARS-CoV-2 at 500 virus copies per reaction ( Table 2) . To confirm the specificity of the primer-probe sets (FAM, HEX, and Cy5 fluorophores) either tested as single or multiplex reactions, as well as in comparison to the original singleplex assay (FAM), we used nasopharyngeal swab and saliva samples from patients to detect SARS-CoV-2 RNA. The Ct values generated by the multiplex RT-qPCR were similar 7 with FAM only or multi-color of singleplex RT-qPCR (Figure 2 and Table 3 ). These data indicated that our RT-qPCR with multicolor fluorophores under single-and multiplex conditions has similar performance for the detection of SARS-CoV-2 RNA as the currently utilized singleplex RT-qPCR. To evaluate the accuracy of our RT-qPCR multiplex assay, we tested RNA extracted RT-qPCR were 100% sensitive as compared with singleplex RT-qPCR (Figure 3 and Table 4 ). These data show that our multiplex RT-qPCR method could provide an alternative to the detection of SARS-CoV-2 by currently published singleplex methods. We developed a multiplex RT-qPCR for molecular diagnostic testing of SARS-CoV-2 by improving on an existing research singleplex RT-qPCR method using the CDC primer-probe sets. This multiplex RT-qPCR approach simultaneously detected the CDC-recommended two gene segments of the SARS-CoV-2 (N1 and N2) and the internal control human RNase P gene in a single reaction for research purposes. This method performed as well as the singleplex RT-qPCR with clinical samples and was very specific for detecting all target genes. Generally, an important consideration for this multiplex RT-qPCR approach is that cycling conditions may vary depending on qPCR machines, sample type and target gene. We therefore recommend that 8 when implementing new assays, primer and probe concentrations should be optimized to individual lab conditions. The US CDC primer and probe sets for COVID-19 testing are recommended for clinical testing in the US [2] . We reported sensitivity of US CDC primer and probe sets compared with others; China CDC [5] , Charité Institute of Virology, Universitätsmedizin Berlin [6] and Hong Kong University [7] . In singleplex RT-qPCR, CDC N2 primer set has a lower detection capability than CDC N1 primers [8] . Our multiplex RT-qPCR assay also showed that N1 and N2 primer-probe set were 60 % and 25 % detection in 50 copies per reaction, respectively ( Table 2) . The SARS-CoV-2 pandemic has already claimed the lives of over 400,000 people, and halted the global economy and changed our daily lives worldwide. A rapid and accurate diagnosis that is not cost prohibitive to test for infected individuals is urgently needed. Our multiplex RT-qPCR protocol described in this study provides rapid and highly sensitive detection of SARS-CoV-2 RNA for research purposes. In the future, FDA approval of such multiplex PCR technique for clinical testing could provide a cost effective solution to mass testing. ( Individual values are indicated in Table 3 . Forty two RNA templates from nasopharyngeal swabs and saliva samples obtained from COVID-19 inpatients or health care worker and positive control (P) (10 3 virus copy per μl) were performed singleplex and multiplex RT-qPCR. Dash line indicates the cut-off value of 38 Ct. Individual values are indicated in Table 4 . 13 Table 1 . Primer and probe for single-and multiplex RT-qPCR Table 2 . Lower limit of detection of SARS-CoV-2 in multiplex RT-qPCR Table 3 . Comparison of Ct value between singleplex and multiplex RT-qPCR N, negative control; P, Positive control (SARS-CoV-2 RNA with a concentration of 10 3 per μl); ND, not detected. 14 Table 4 . The Ct value and result from multiplex assay in clinical samples RP, human RNase P; P, Positive control (SARS-CoV-2 RNA with a concentration of 10 3 viral copies per μl); ND, not detected; NP, nasopharyngeal swab. (1, 742) Coronavirus disease 2019 (COVID-19) Situation Report -101 US_CDC. US_CDC 2019-Novel Coronavirus (2019-nCoV) Real-time rRT-PCR Panel: Primers and Probes Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient Specific primers and probes for detection 2019 novel coronavirus Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR primer-probe sets